Corbus Pharmaceuticals Holdings (STU:3371) Cyclically Adjusted PB Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:3371 Corbus Pharmaceuticals Holdings Inc STU:3371
31 GF Score
Price €8.70
! 1 Warning Sign
View Full Analysis

What is Corbus Pharmaceuticals Holdings Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Corbus Pharmaceuticals Holdings  (STU:3371) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Corbus Pharmaceuticals Holdings Cyclically Adjusted PB Ratio Related Terms


Corbus Pharmaceuticals Holdings Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Corbus Pharmaceuticals Holdings's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corbus Pharmaceuticals Holdings Cyclically Adjusted PB Ratio Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.38 0.72 0.49

Corbus Pharmaceuticals Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.76 0.49 0.55 0.00

STU:3371 vs OKUR, HUMA, TNYA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corbus Pharmaceuticals Holdings Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's Cyclically Adjusted PB Ratio falls into.


STU:3371
31GF Score
Corbus Pharmaceuticals Holdings Inc STU:3371
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corbus Pharmaceuticals Holdings Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Corbus Pharmaceuticals Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Corbus Pharmaceuticals Holdings's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=4.573/333.9520*333.9520
=4.573

Current CPI (Jun. 2026) = 333.9520.

Corbus Pharmaceuticals Holdings Quarterly Data

Book Value per Share CPI Adj_Book
201609 8.092 241.428 11.193
201612 5.678 241.432 7.854
201703 24.388 243.801 33.406
201706 19.983 244.955 27.243
201709 16.028 246.819 21.686
201712 26.350 246.524 35.695
201803 27.902 249.554 37.338
201806 24.919 251.989 33.024
201809 19.256 252.439 25.474
201812 12.680 251.233 16.855
201903 17.420 254.202 22.885
201906 19.455 256.143 25.365
201909 12.483 256.759 16.236
201912 2.571 256.974 3.341
202003 8.500 258.115 10.997
202006 15.988 257.797 20.711
202009 9.056 260.280 11.619
202012 11.295 260.474 14.481
202103 18.444 264.877 23.254
202106 15.322 271.696 18.833
202109 15.809 274.310 19.246
202112 14.653 278.802 17.552
202203 13.300 287.504 15.449
202206 11.207 296.311 12.631
202209 10.145 296.808 11.415
202212 7.467 296.797 8.402
202303 3.647 301.836 4.035
202306 1.987 305.109 2.175
202309 0.066 307.789 0.072
202312 -1.431 306.746 -1.558
202403 8.490 312.332 9.078
202406 10.143 314.175 10.781
202409 11.134 315.301 11.793
202412 11.168 315.605 11.817
202503 9.611 319.799 10.036
202506 7.853 322.561 8.130
202509 6.263 324.800 6.439
202512 7.152 324.054 7.370
202603 6.161 330.213 6.231
202606 4.573 333.952 4.573

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Corbus Pharmaceuticals Holdings Business Description

Other Exchanges CRBP:USA0SZI:UK
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
31GF Score

Get the complete analysis for STU:3371

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.70
Price